Business
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance RAP-219 Phase 3 program in FOS remains on track for initiation in the second quarter of 2026 Pipeline programs, including RAP-219 long-acting injectable formulation, RAP
About this update from Rapport Therapeutics, Inc.
[{"type":"image","alt":"Rapport Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Rapport Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":153,"url":"https://media.zenfs.com/en/globenewswire.com/398dec8a80e8c3a1c183590a167a19e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bJEA9v0oN3uart2zzjf72Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNA--/https://media.zenfs.com/en/globenewswire.com/398dec8a80e8c3a1c183590a167a19e7","width":300,"height":153},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/bJEA9v0oN3uart2zzjf72Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNA--/https://media.zenfs.com/en/globenewswire.com/398dec8a80e8c3a1c183590a167a19e7","width":300,"height":153}},"lazy":false},{"type":"text","content":"Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 ","length":196,"tagName":"p"},{"type":"text","content":"RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance","length":138,"tagName":"p"},{"type":"text","content":"RAP-219 Phase 3 program in FOS remains on track for initiation in the second quarter of 2026","length":92,"tagName":"p"},{"type":"text","content":"Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and α6β4 nAChR in chronic pain and migraine, continue to advance","length":191,"tagName":"p"},{"type":"text","content":"Strategic collaboration and license agreement entered into with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications","length":158,"tagName":"p"},{"type":"text","content":"Ended the first quarter of 2026 with $476.8 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029","length":189,"tagName":"p"},{"type":"text","content":"BOSTON and SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, ...